Brain+ begins early activity and brand building in the US
Brain+ begins early activity and brand building in the US The United States (US) is a key future market for Brain+, and early brand building and exploration is now ongoing Brain+ has been selected and featured as a 2022 TMC-Denmark BioBridge Partner in the new Texas Medical Center (TMC) 2022 Biobridge e-book. TMC is the […]
First milestone met
Brain+ meets milestone with Rox Health (Roche Germany) Rox Health has approved the German version of Brain+’s first digital dementia product, CST-Therapist Companion, for commercial launch. Meeting this milestone unlocks access for Brain+ to additional expert resources in the Rox Health/Roche organization and triggers a minor milestone payment. The following milestones will be product launch […]
Growing interest in DTx from big pharma
Brain+ is experiencing growing interest from big pharma in its Digital Therapeutics solutions for dementia. Brain+ is a first mover in the field of Digital Therapeutics (DTx) solutions to treat Alzheimer’s Disease (AD) and other types of dementia and help relieve the growing burden of these conditions on patients, relatives, and societies. According to the […]
Growing interest in DTx from big pharma
Brain+ is experiencing growing interest from big pharma in its Digital Therapeutics solutions for dementia. Brain+ is a first mover in the field of Digital Therapeutics (DTx) solutions to treat Alzheimer’s Disease (AD) and other types of dementia and help relieve the growing burden of these conditions on patients, relatives, and societies. According to the […]
